Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
The Boehringer Ingelheim group of companies' objectives and beliefs can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision.
Research & Development
Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need.
How We Discover
From initial discovery to a marketable medicine is a long, challenging road. It takes about 12 - 15 years from discovery to the approved medication and requires an investment of about US $1 billion.
Working at Boehringer Ingelheim – Being part of a global family
As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in the world.
Animal Health: One business, one vision, one global leader in disease prevention and treatment
By bringing together the best minds in the business, Boehringer Ingelheim and Merial have united to create one animal health company with the portfolio, scale and talent to make the industry even better at improving animal health.
02 Jan 2017 at 07:00
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Boehringer Ingelheim & Merial
Joachim Hasenmaier talks about Animal Health
Joachim Hasenmaier, Head of the Boehringer Animal Health Business Unit, speaks about the coming together of Merial and Boehringer Ingelheim.
DOWNLOAD PDF (1.23 MB)
Get the facts
Read our latest fact sheet on the Boehringer Ingelheim Animal Health business.
New company video of Boehringer Ingelheim – Value through Innovation
@BOEHRINGER 11 Oct 2016 at 11:36
Making More Health
For new and better ways of improving health around the globe!
New Member of the Board of Managing Directors of Boehringer Ingelheim/ Responsible for Corporate Board Division Finance
Partnerships are important in creating innovation. Read more about Dr Paola Casarosa and her work on developing therapeutic alliances and strategic partnerships.